Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 5:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 396 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard antibiotic therapy Clear all
Withdrawn Phase 2 Interventional

ERAdicate S. Aureus in Patients With Bacteremia and Endocarditis

NCT05329168
View directory record Official record
Conditions
Bacteremia Due to Staphylococcus Aureus, Left Sided Infective Endocarditis (Disorder), Right Sided Infective Endocarditis (Disorder), Endocarditis Infective
Interventions
Tonabacase (LSVT-1701)
Drug
Lead sponsor
Lysovant
Industry
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Butte, Montana
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 2, 2026, 5:10 AM EDT
Completed Phase 1 Interventional

PK and Safety Evaluation of Daptomycin in Children Ages 2-6 With Proven or Suspected Gram-positive Infections

NCT00679835
View directory record Official record
Conditions
Gram Positive Infection, Concurrent Antibiotic Treatment
Interventions
daptomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
2 Years to 6 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 2, 2026, 5:10 AM EDT
Not listed Not applicable Interventional

Non-invasive Fluid Management

NCT02892799
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
NICOM-Guided Diuresis, Standard of Care
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Oct 2, 2026, 5:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Facial Effleurage on Acute Rhinosinusitis

NCT04642989
View directory record Official record
Conditions
Rhinosinusitis Acute
Interventions
Sham Treatment, Facial Effleurage, Antibiotics
Other · Drug
Lead sponsor
Edward Via Virginia College of Osteopathic Medicine
Other
Eligibility
18 Years to 69 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Oct 2, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam

NCT03485950
View directory record Official record
Conditions
Other Infectious Diseases
Interventions
Cefepime, Ceftolozane, Laboratory Biomarker Analysis, Meropenem, Piperacillin-Tazobactam, Tazobactam
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 2, 2026, 5:10 AM EDT
Not listed Not applicable Interventional

Safety Study of a Novel Wearable Phototherapy System for the Management of Acute Burn Wounds

NCT03948360
View directory record Official record
Conditions
Burn Wound
Interventions
Low-Irradiance Monochromatic Biostimulation (LIMB) Device, Standard of Care
Device · Other
Lead sponsor
Rogers Sciences Inc.
Industry
Eligibility
Up to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Oct 2, 2026, 5:10 AM EDT
Completed Not applicable Interventional

Subcutaneous Injection and Ultrasonic Dispersion of Cefazolin Into Chronic Pelvic-Region Pressure Ulcers in Persons With Spinal Cord Injury

NCT02584426
View directory record Official record
Conditions
Spinal Cord Injury, Chronic Pressure Ulcers
Interventions
Ultrasonic Distribution of Cefazolin
Device
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 79 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 2, 2026, 5:10 AM EDT
Completed Not applicable Interventional

Combining Opioid Addiction Treatment Services With CARe for Infectious Endocarditis

NCT03048643
View directory record Official record
Conditions
Endocarditis, Bacterial, Opioid-use Disorder, Buprenorphine, Outpatient Parenteral Antibiotic Therapy
Interventions
Outpatient parenteral antibiotic therapy
Behavioral
Lead sponsor
Laura Fanucchi
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 2, 2026, 5:10 AM EDT
Completed Phase 4 Interventional Results available

Duration of Antibiotic Therapy as Part of Maximal Medical Therapy for Chronic Rhinosinusitis

NCT01825408
View directory record Official record
Conditions
Sinusitis
Interventions
Doxycycline, Azithromycin, Augmentin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 2, 2026, 5:10 AM EDT
Completed Phase 3 Interventional Results available

Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

NCT02714595
View directory record Official record
Conditions
Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP), Complicated Urinary Tract Infection (cUTI), Sepsis, Ventilator Associated Pneumonia (VAP)
Interventions
Cefiderocol, Best Available Therapy
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Hartford, Connecticut • Newark, Delaware • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 2, 2026, 5:10 AM EDT
Completed Not applicable Interventional

Viral Testing and Biomarkers to Reduce Antibiotic Use for Respiratory Infections

NCT01907659
View directory record Official record
Conditions
Respiratory Infections
Interventions
Release of test results
Other
Lead sponsor
University of Rochester
Other
Eligibility
21 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 2, 2026, 5:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Medical and Surgical Treatment of Uncomplicated Acute Appendicitis in Children

NCT02991937
View directory record Official record
Conditions
Appendicitis
Interventions
Piperacillin/Tazobactam, Surgical Treatment
Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
6 Years to 17 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 2, 2026, 5:10 AM EDT
Suspended No phase listed Observational

Assessment of Patients With Acute Pouchitis Treated With Antibiotics

NCT05252273
View directory record Official record
Conditions
Pouchitis, Ulcerative Colitis
Interventions
Observational, No intervention
Other
Lead sponsor
Alimentiv Inc.
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 2, 2026, 5:10 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Weekly Isotretinoin vs Tetracycline for Moderate Acne

NCT06225570
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Isotretinoin, Tetracycline
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
12 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 2, 2026, 5:10 AM EDT
Terminated No phase listed Observational

Sensitivity of Extended Cultures in Diagnosing Urinary Tract Infections

NCT03080389
View directory record Official record
Conditions
Overactive Bladder, Overactive Detrusor, Urgency-Frequency Syndrome, UTI
Interventions
Extended Urine Culture
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Oct 2, 2026, 5:10 AM EDT
Withdrawn Phase 4 Interventional

Use of Bismuth Subsalicylate in Clostridium Difficile Colitis

NCT03592082
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Bismuth Subsalicylate, standard antibiotic therapy
Drug
Lead sponsor
Bassett Healthcare
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Cooperstown, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Oct 2, 2026, 5:10 AM EDT
Completed Phase 4 Interventional Results available

Standardized Treatment of Pulmonary Exacerbations II

NCT02781610
View directory record Official record
Conditions
Pulmonary Cystic Fibrosis
Interventions
Standard of care IV antibiotic(s)
Drug
Lead sponsor
Chris Goss
Other
Eligibility
18 Years and older
Enrollment
982 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
57
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 2, 2026, 5:10 AM EDT
Withdrawn Not applicable Interventional

iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes

NCT03446638
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
FDA-approved drug or combination of drugs, FLAG induction, 7 + 3 induction, Low-dose cytarabine, Supportive care alone, Computational biology simulations software
Drug · Other · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 2, 2026, 5:10 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis

NCT03091439
View directory record Official record
Conditions
Osteomyelitis
Interventions
Dalbavancin, Standard of Care
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Ft. Pierce, Florida
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 2, 2026, 5:10 AM EDT
Active, not recruiting Early Phase 1 Interventional

Bladder Preservation or Cystectomy for MIBC

NCT07821177
View directory record Official record
Conditions
Muscle-Invasive Bladder Carcinoma, Bladder Cancer, Urothelial Carcinoma
Interventions
Gemzar, Cisplatin, Adrucil, Mitomycin, Radical Cystectomy
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 2, 2026, 5:10 AM EDT
Enrolling by invitation Not applicable Interventional

Assessing Post-operative Outcomes After Children's Sistrunk Procedure With or Without a Drain

NCT07148895
View directory record Official record
Conditions
Thyroglossal Duct Cysts
Interventions
Post-surgical drain, No post-surgical drain
Procedure
Lead sponsor
University of Rochester
Other
Eligibility
3 Years to 17 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
5
States / cities
Los Angeles, California • Hartford, Connecticut • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 2, 2026, 5:10 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Novel Probiotic-antibiotic Combination to Prevent Recurrent Urinary Tract Infections

NCT06149676
View directory record Official record
Conditions
Recurrent Uti
Interventions
Saccharomyces Boulardii 250 MG [Florastor]
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
2 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 2, 2026, 5:10 AM EDT
No Longer Available No phase listed Expanded access Accepts healthy volunteers

Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersion

NCT01238276
View directory record Official record
Conditions
Infection, Soft Tissue, Infection, Wound, Cellulitis, Diabetic Foot Ulcer
Interventions
Cefazolin, Silberg Tissue Preparation System
Drug · Device
Lead sponsor
Sonescence, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Sebastopol, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 2, 2026, 5:10 AM EDT
Not yet recruiting Early Phase 1 Interventional

Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy

NCT06884748
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
Ursodiol 500 MG
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 2, 2026, 5:10 AM EDT